Nursing Care in Benzodiazepines
Nursing Care in Benzodiazepines
Nursing Care in Benzodiazepines
ANTIHYPERTENSIVE
NURSING CARE
Blood pressure control
Monitor signs of hyperk (IRAP, HEP, DM)
Assess for signs of angioedema
Control of liver and kidney function
Instruct the patient not to drink alcohol or take other medications that depress the
CNS while taking the medications.
Sexual dysfunction:
a) Men may report abnormal ejaculation or impotence.
b) Women may experience delay or loss of orgasm.
c) If the side effects become intolerable, it may be necessary to change the
medication to another antidepressant.
IMPORTANT POINTS FOR NURSING
Do not stop the medication abruptly after a long period of use, as withdrawal symptoms
may occur: nausea, vomiting.
Get up slowly from sitting or lying down to prevent a sudden drop in blood pressure.
DIAZEPAN TAB.
BENZODIAZEPINE
NURSING INTERVENTION
Care of vital signs with emphasis on HR
Orthostatic hypotension
Orthostatic hypotension
*Check blood pressure at rest and standing, and any changes in pulse. *Instruct
the patient to get up slowly from lying or sitting.
Observe signs of poisoning
Ensure the expected therapeutic response
Instruct the patient not to drive a car or dangerous machinery while taking the
medications.
Instruct the patient in long-term treatment so that he does not stop taking the
medication abruptly, as this may be life-threatening. Symptoms include
depression, insomnia, increased anxiety, abdominal and muscle pain, tremors,
vomiting, sweating, seizures, and delirium.
Assess the patient's mood daily.
Take necessary precautions if potential suicide exists.
Take the medicine with food and milk.
Observe adverse reactions
IMPORTANT POINTS FOR NURSING
Give general advice on adequate sleep hygiene: do not sleep during the day, do not
drink stimulating substances (coffee, tea, cola drinks, alcohol) during the afternoon,
avoid noisy or very bright environments at night, avoid heavy dinners, etc
Due to the risk of dependence and tolerance that hypnotics entail, it is recommended to
restrict their use to specific situations and maintain them for as short a time as possible,
as well as withdraw them gradually to avoid the appearance of possible withdrawal
symptoms.
Milvia
THEORETICAL FRAMEWORK
ANTIHYPERTENSIVES
High blood pressure (HTN) is one of the main risk factors for vascular diseases in
developed countries, its importance being known not only in the healthcare field but also in
the general population. It constitutes a problem of great magnitude with clinical, social and
economic implications; and in many countries it is the most frequent cause of medical
consultation and the one that generates the greatest demand for the use of drugs. The
prevalence varies according to the figures taken as pathological, and it is estimated that
15-30% of the adult population has this pathology. Regarding its etiology, it is unknown in
90% of cases, and is identified as essential or primary.
They are those drugs indicated in the treatment of HTN, which are classified
according to the blood pressure values proposed by the seventh report of the Joint
National Committee of the United States (table 27-1).
Classification
Currently, a wide variety of drugs are available, which must be effective and safe,
and their selection will be individualized according to the clinical characteristics of the
patient. The pharmacological mechanisms through which the different drugs act are: a)
reducing blood volume and, therefore, cardiac output and blood pressure; b) decreasing
peripheral resistance through sympathetic inhibition, direct vasodilation or decrease in
vascular reactivity; c) decreasing cardiac output, and d) inhibiting the reninangiotensin
axis. According to this classification, there are seven types of antihypertensive drugs:
diuretics, adrenergic inhibitors (β-blockers, α1-blockers, α/β-blockers), direct vasodilators,
calcium antagonists, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II
receptors (ARA-II) and centrally acting hypotensive agents.
THEORETICAL FRAMEWORK
BENZODIAZEPINES
Mechanism of action.
They increase the inhibitory effects of GABA, since they facilitate its binding with
GABAA receptors, which are associated with chloride channels. Benzodiazepines bind to
a specific benzodiazepine receptor located in the macromolecular complex formed by the
GABAA receptor and the chloride channel, producing an allosteric modulation that
facilitates the interaction of GABA with its specific binding site, increasing the opening
frequency of the channels. of chlorine activated by it. Not only classic benzodiazepines
bind to this receptor, but also other non-benzodiazepine molecules that act as agonists
(such as zopiclone or zolpidem) or antagonists (such as flumazenil). Furthermore, in this
complex there are other binding sites for barbiturates, picrotoxin, general anesthetics and
steroids, which also modify the opening of the channel in a facilitative or inhibitory way in
response to GABA.(1)
Pharmacokinetics.
They are well absorbed orally, and maximum absorption occurs between 30 and
180 minutes (some do so more quickly than others, depending on the degree of lipid
solubility). By intramuscular route, most have slow and erratic absorption (especially
diazepam and chlordiazepoxide), producing insufficient plasma concentrations and local
irritation due to crystallization of the compound at the injection site. The intravenous route
is used in emergencies, usually anticonvulsants. Another alternative route is the rectal
route, especially in children, through which diazepam solutions are rapidly absorbed.
Benzodiazepines are generally very fat-soluble, which means that many of them gradually
accumulate in body fat, and their distribution is broad, easily crossing the placenta and the
blood-brain barrier.
Adverse effects.
Drug interactions.
They enhance the central nervous system depressant effects of other drugs
(alcohol, barbiturates, antipsychotics, opiates, sedative antihistamines). The interaction
with alcohol is of special importance, due to the danger it poses for drivers, since it can
alter the state of consciousness and the ability to drive. (1)
1. Hurlé MA. Anxiolytic and sedative drugs. In: Flórez J, Armijo JA, Mediavilla A, editors. Human pharmacology.
2. Catalog of pharmaceutical specialties. General Council of Pharmaceutical Colleges, Einsa. Madrid; 2005.